C
Catalin Codreanu
Researcher at Carol Davila University of Medicine and Pharmacy
Publications - 100
Citations - 2080
Catalin Codreanu is an academic researcher from Carol Davila University of Medicine and Pharmacy. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 17, co-authored 64 publications receiving 1547 citations. Previous affiliations of Catalin Codreanu include Hai phong University Of Medicine and Pharmacy.
Papers
More filters
Journal ArticleDOI
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe,Robert Landewé,Claire Daien,C. Hua,Daniel Aletaha,José María Álvaro-Gracia,Margot Bakkers,Nina Brodin,Gerd R Burmester,Catalin Codreanu,Richard Conway,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,João Eurico Fonseca,Karim Raza,Lucía Silva-Fernández,Josef S Smolen,Diana Skingle,Zoltán Szekanecz,Tore K Kvien,Annette H M van der Helm-van Mil,Ronald F van Vollenhoven +22 more
TL;DR: These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
Journal ArticleDOI
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
D. van der Heijde,Lars Klareskog,Robert Landewé,George A W Bruyn,Alain Cantagrel,Patrick Durez,Gabriel Herrero-Beaumont,Yair Molad,Catalin Codreanu,Gabriele Valentini,R. Zahora,Ronald Pedersen,D. MacPeek,Joseph Wajdula,Saeed Fatenejad +14 more
TL;DR: Etanercept plus methotrexate showed sustained efficacy through 3 years and remained more effective than either monotherapy, even after adjustment for patient withdrawal.
Journal ArticleDOI
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Hanna W. van Steenbergen,Daniel Aletaha,Liesbeth J J Beaart-van de Voorde,Elisabeth Brouwer,Catalin Codreanu,Bernard Combe,João Eurico Fonseca,Merete Lund Hetland,Frances Humby,Tore K Kvien,Karin Niedermann,Laura Nuño,Sue Oliver,Solbritt Rantapää-Dahlqvist,Karim Raza,Dirkjan van Schaardenburg,Georg Schett,Liesbeth De Smet,Gabriella Szücs,Jirí Vencovský,Piotr Wiland,Maarten de Wit,Robert Landewé,Annette H M van der Helm-van Mil +23 more
TL;DR: A set of clinical characteristics for patients with arthralgia who are at risk of progression to RA was established by experts based on their clinical experience.
Journal ArticleDOI
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results
D. van der Heijde,Lars Klareskog,Maarten Boers,Robert Landewé,Catalin Codreanu,H.D. Bolosiu,Ronald Pedersen,Saeed Fatenejad +7 more
TL;DR: DAS and DAS28 remission results were similar for assessing achieving and sustaining remission in RA, frequently differing from patients classified as ACR70 responders and three methods of examining duration of remission produced comparable results.
Journal ArticleDOI
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
Bernard Combe,Catalin Codreanu,U Fiocco,M Gaubitz,Piet Geusens,Tore K Kvien,Karel Pavelka,Ph N Sambrook,Josef S. Smolen,Joseph Wajdula,Saeed Fatenejad +10 more
TL;DR: For all efficacy variables assessed, etanercept alone or in combination with sulfasalazine resulted in substantial and similar improvement in disease activity from baseline to week 24 compared with sulf asalazine alone in patients with active rheumatoid arthritis despite their sulfasAlazine treatment.